A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells
- Amélie Fouqué, Olivier Delalande, Mickael Jean, Rémy Castellano, Emmanuelle Josselin, Marine Malleter, Kenji F. Shoji, Mac Dinh Hung, Hariniaina Rampanarivo, Yves Collette, Pierre van de Weghe*, and Patrick Legembre*
- J. Med. Chem., Article ASAP
- DOI: 10.1021/acs.jmedchem.5b00991
- Publication Date (Web): August 3, 2015
- Copyright © 2015 American Chemical Society
- *Phone: (+33)-2-2323-3803. Fax: (+33)-2-2323-4425. E-mail: email@example.com.
- *Phone: (+33)-2-2323-7241. Fax: (+33)-2-9925-3164. E-mail: firstname.lastname@example.org.
ABSTRACT: Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3K catalytic subunits, several rounds of chemical syntheses led to the generation of a new collection of chromologues that showed enhanced ability to kill PI3K-addicted cancer cells and to inhibit Akt phosphorylation at serine 473, a hallmark of PI3K/mTOR activation. This initial screen uncovered a chromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines. Strikingly, DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases).
Finally, in vivo, this novel drug was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
Read the news on the official website here.